ContraVir Pharmaceuticals announces pricing of $15.6 million public offering
ContraVir Pharma announced pricing of a public offering with expected gross proceeds of $15.6 million. Roth Capital Partners is acting as the lead placement agent for the offering. Arcadia Securities is acting as co-placement agent for the offering. June 18, 2019